GPC3 and lung carcinoma: It might be a non-invasive diagnostic and prognostic marker for NSCLC and could affect the migration, invasion, and cisplatin resistance of lung cancer cells by targeting glypican-3 (GPC3) and SAMD9 [70,71,72].